Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) following autologous stem cell transplant (ASCT) remain a management challenge with few reliably effective treatments. Lenalidomide, an immunomodulatory drug approved for patients with myelodysplastic syndrome with del(5q),...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Helen, Cheng, Bin, Montanari, Francesca, Lue, Jennifer K., Deng, Changchun, Marchi, Enrica, O’ Connor, Owen A., Sawas, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534065/
https://www.ncbi.nlm.nih.gov/pubmed/33062232
http://dx.doi.org/10.1177/2040620720947340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534065/
https://www.ncbi.nlm.nih.gov/pubmed/33062232
http://dx.doi.org/10.1177/2040620720947340

Ejemplares similares